林业发展局快速跟踪两种抗药性感染的快速测试,如MRSA和CRE。 FDA fast-tracks two rapid tests for drug-resistant infections like MRSA and CRE.

美国食品和药物管理局已授予两种由哈迪诊断公司开发的快速诊断测试突破性设备名称,旨在检测耐药病原体,如MRSA和耐卡巴胺的肠杆菌. The FDA has granted Breakthrough Device Designation to two rapid diagnostic tests developed by Hardy Diagnostics, designed to detect drug-resistant pathogens like MRSA and carbapenem-resistant Enterobacteriaceae. 该指定旨在加速发展和审查,支持更快地诊断和治疗严重感染。 The designation aims to expedite development and review, supporting faster diagnosis and treatment of serious infections. 这些测试旨在通过更快地发现临床环境中的抗药性细菌,改善患者的结果。 These tests are intended to improve patient outcomes by enabling quicker identification of resistant bacteria in clinical settings.